Persistent URL of this record https://hdl.handle.net/1887/104683
In Collections
This item can be found in the following collections:
Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST) Subgroup analysis of outcomes based on pretreatment characteristics
- All authors
- Joensuu, H.; Casali, P.G.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; Gelderblom, H.; Hohenberger, P.; Leahy, M.G.; Mehren, M. von; Badalamenti, G.; Blackstein, M.E.; Cesne, A. le; Schoffski, P.; Maki, R.G.; Xu, J.M.; Nishida, T.; Kappeler, C.; Kuss, I.; Demetri, G.D.
- Date
- 2013-05-20
- Journal
- Journal of Clinical Oncology
- Volume
- 31
- Issue
- 15